UY32748A - 2-carboxamida-cicloamino-ureas - Google Patents
2-carboxamida-cicloamino-ureasInfo
- Publication number
- UY32748A UY32748A UY0001032748A UY32748A UY32748A UY 32748 A UY32748 A UY 32748A UY 0001032748 A UY0001032748 A UY 0001032748A UY 32748 A UY32748 A UY 32748A UY 32748 A UY32748 A UY 32748A
- Authority
- UY
- Uruguay
- Prior art keywords
- cicloamino
- carboxamida
- ureas
- compounds
- phosphatidyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
Abstract
La presente invención se refiere a los compuestos de la fórmula I: y a las sales de los mismos, en donde los sustituyentes son como se definen en la descripción, a composiciones, y al uso de los compuestos en el tratamiento de enfermedades mitigadas por la inhibición de la cinasa de fosfatidil-inositol-3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27002809P | 2009-07-02 | 2009-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY32748A true UY32748A (es) | 2011-01-31 |
Family
ID=42357253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001032748A UY32748A (es) | 2009-07-02 | 2010-06-30 | 2-carboxamida-cicloamino-ureas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8357707B2 (es) |
| EP (1) | EP2448946B1 (es) |
| JP (1) | JP2012531454A (es) |
| KR (1) | KR20120046723A (es) |
| CN (1) | CN102471351A (es) |
| AR (1) | AR077366A1 (es) |
| AU (1) | AU2010268058A1 (es) |
| BR (1) | BR112012000035A2 (es) |
| CA (1) | CA2766853A1 (es) |
| EA (1) | EA201200087A1 (es) |
| ES (1) | ES2432671T3 (es) |
| MX (1) | MX2012000178A (es) |
| TW (1) | TW201103944A (es) |
| UY (1) | UY32748A (es) |
| WO (1) | WO2011000855A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8293753B2 (en) * | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| RU2014149145A (ru) | 2012-05-23 | 2016-07-20 | Ф. Хоффманн-Ля Рош Аг | Композиции и способы получения и применения эндодермальных клеток и гепатоцитов |
| LT3129021T (lt) * | 2014-04-08 | 2020-12-10 | Incyte Corporation | B ląstelių piktybiškumo gydymas jak ir pi3k inhibitorių deriniu |
| KR20170084558A (ko) * | 2016-01-12 | 2017-07-20 | 삼성전자주식회사 | 전자 장치 및 그의 동작 방법 |
| CN106946669B (zh) * | 2017-03-21 | 2020-09-15 | 国家电网公司 | 一种环保绝缘气体联产工艺及工业化生产装置 |
| CN106986757B (zh) * | 2017-04-24 | 2020-11-24 | 国家电网公司 | 一种环保绝缘气体生产工艺及工业生产装置 |
| CN107935884B (zh) * | 2017-11-30 | 2020-06-12 | 北京宇极科技发展有限公司 | 全氟腈的制备方法 |
| CN108424375B (zh) * | 2018-04-20 | 2020-06-02 | 北京宇极科技发展有限公司 | 全氟腈的制备方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57175189A (en) | 1981-04-21 | 1982-10-28 | Kyowa Hakko Kogyo Co Ltd | Benzothiazole derivative and its preparation |
| MY156407A (en) | 2002-02-28 | 2016-02-26 | Novartis Ag | 5-phenylthiazole derivatives and use as p13 kinase inhibitors |
| US7632858B2 (en) | 2002-11-15 | 2009-12-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
| GB0305152D0 (en) | 2003-03-06 | 2003-04-09 | Novartis Ag | Organic compounds |
| TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
| GB0315966D0 (en) | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
| GB0320197D0 (en) | 2003-08-28 | 2003-10-01 | Novartis Ag | Organic compounds |
| ZA200602755B (en) | 2003-09-06 | 2007-06-27 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
| NZ548197A (en) | 2004-01-12 | 2010-06-25 | Serono Lab | Thiazole derivatives and use thereof |
| GB0415364D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| UY29149A1 (es) | 2004-10-07 | 2006-05-31 | Boehringer Ingelheim Int | Tiazolil-dihidro-indazoles |
| RU2403258C2 (ru) * | 2004-10-07 | 2010-11-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Тиазолилдигидроиндазолы |
| DE102004048877A1 (de) | 2004-10-07 | 2006-04-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | PI3-Kinasen |
| GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
| US7799814B2 (en) | 2005-05-24 | 2010-09-21 | Merck Serono S.A. | Thiazole derivatives and use thereof |
| DE102005048072A1 (de) | 2005-09-24 | 2007-04-05 | Bayer Cropscience Ag | Thiazole als Fungizide |
| WO2007070600A2 (en) | 2005-12-12 | 2007-06-21 | Genelabs Technologies, Inc. | N-(5-membered heteroaromatic ring)-amido anti-viral compounds |
| ITRM20050166U1 (it) * | 2005-12-15 | 2007-06-16 | Salice Arturo Spa | Cerniera per mobile. |
| GB0525671D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| WO2007082956A1 (en) | 2006-01-23 | 2007-07-26 | Laboratoires Serono S.A. | Thiazole derivatives and use thereof |
| PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| US7691868B2 (en) | 2006-04-06 | 2010-04-06 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-quinazoline |
| US20070238746A1 (en) | 2006-04-06 | 2007-10-11 | Trixi Brandl | Thiazolyl-dihydro-chinazoline |
| US7517995B2 (en) | 2006-04-06 | 2009-04-14 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-cyclopentapyrazole |
| US8173638B2 (en) | 2006-11-21 | 2012-05-08 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| WO2008064218A2 (en) | 2006-11-21 | 2008-05-29 | Smithkline Beecham Corporation | Amido anti-viral compounds |
| WO2008124000A2 (en) | 2007-04-02 | 2008-10-16 | Ligand Pharmaceuticals Incorporated | Thiazole derivatives as androgen receptor modulator compounds |
| US20090004140A1 (en) | 2007-06-26 | 2009-01-01 | Yao-Ling Qiu | 4-substituted pyrrolidine as anti-infectives |
| AU2008277628B2 (en) * | 2007-07-18 | 2012-03-15 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| WO2009080694A1 (en) * | 2007-12-20 | 2009-07-02 | Novartis Ag | Thiazole derivatives used as pi 3 kinase inhibitors |
| PL2276767T3 (pl) * | 2008-03-31 | 2014-09-30 | Genentech Inc | Związki benzopiranowe i benzoksepinowe będące inhibitorami pi3k oraz metody ich stosowania |
-
2010
- 2010-06-30 EA EA201200087A patent/EA201200087A1/ru unknown
- 2010-06-30 EP EP10729848.1A patent/EP2448946B1/en not_active Not-in-force
- 2010-06-30 CN CN2010800300631A patent/CN102471351A/zh active Pending
- 2010-06-30 MX MX2012000178A patent/MX2012000178A/es not_active Application Discontinuation
- 2010-06-30 JP JP2012518082A patent/JP2012531454A/ja active Pending
- 2010-06-30 BR BR112012000035A patent/BR112012000035A2/pt not_active Application Discontinuation
- 2010-06-30 WO PCT/EP2010/059254 patent/WO2011000855A1/en not_active Ceased
- 2010-06-30 CA CA2766853A patent/CA2766853A1/en not_active Abandoned
- 2010-06-30 UY UY0001032748A patent/UY32748A/es not_active Application Discontinuation
- 2010-06-30 ES ES10729848T patent/ES2432671T3/es active Active
- 2010-06-30 AU AU2010268058A patent/AU2010268058A1/en not_active Abandoned
- 2010-06-30 KR KR1020127002799A patent/KR20120046723A/ko not_active Withdrawn
- 2010-07-01 TW TW099121706A patent/TW201103944A/zh unknown
- 2010-07-01 AR ARP100102353A patent/AR077366A1/es unknown
- 2010-07-02 US US12/829,526 patent/US8357707B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2448946A1 (en) | 2012-05-09 |
| KR20120046723A (ko) | 2012-05-10 |
| US8357707B2 (en) | 2013-01-22 |
| WO2011000855A1 (en) | 2011-01-06 |
| JP2012531454A (ja) | 2012-12-10 |
| US20110003786A1 (en) | 2011-01-06 |
| CN102471351A (zh) | 2012-05-23 |
| AU2010268058A1 (en) | 2012-01-19 |
| ES2432671T3 (es) | 2013-12-04 |
| CA2766853A1 (en) | 2011-01-06 |
| BR112012000035A2 (pt) | 2018-06-19 |
| AR077366A1 (es) | 2011-08-24 |
| TW201103944A (en) | 2011-02-01 |
| EP2448946B1 (en) | 2013-07-24 |
| MX2012000178A (es) | 2012-02-28 |
| EA201200087A1 (ru) | 2012-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY32747A (es) | 2-carboxamida-cicloamino-ureas sustituidas | |
| CO6321276A2 (es) | Derivados de tiazol usados como inhibidores de pi3- cinasa | |
| NI201100049A (es) | Compuestos orgánicos. | |
| ECSP10010582A (es) | Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer | |
| CO6470845A2 (es) | Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales | |
| CO6491116A2 (es) | Derivados de 5-fluoropirimidinona | |
| UY33337A (es) | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS | |
| CR10233A (es) | Piridin-4-ilmetilamidas | |
| ECSP109922A (es) | Compuestos de pirazol y su uso como inhibidores raf | |
| UY32543A (es) | Análogos de isoxazol-3(2h)-ona como agentes terapéuticos | |
| ECSP12012065A (es) | Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos | |
| CU24039B1 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
| CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
| UY32748A (es) | 2-carboxamida-cicloamino-ureas | |
| CR20120264A (es) | Compuestos | |
| UY32494A (es) | Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones | |
| ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| CR11620A (es) | Derivados de Imadazo-[1,2,b]-Piridazina para el Tratamiento de Enfermedad Mediada por Cinosa de Tirosina C-Met | |
| ECSP11011079A (es) | Nuevos compuestos de hidroxiareno. | |
| DOP2009000287A (es) | Oxazolidinonas sustituidas y su uso | |
| ECSP13012494A (es) | Inhibidores de oxadiazol de la producción de leucotrieno. | |
| CR20160455A (es) | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILA | |
| ECSP11011485A (es) | Espiro-epóxidos como productos intermedios. | |
| ECSP13012548A (es) | Inhibidores de oxadiazol de la producción de leucotrienos. | |
| CU20110108A7 (es) | [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20190207 |